OUR THERAPEUTIC AREAS
Focus on three key therapeutic areas
Patients give meaning to our science and our work. While our innovative therapies are developed through Servier global research and manufacturing network, we are dedicated to making these advanced treatments accessible to diverse healthcare needs of patients in India. By focusing on key areas such as Cardio-metabolism, Venous Diseases and Oncology, we aim to improve the quality of life for millions of patients by addressing their unmet needs and unique challenges that they are faced in their disease journey.
Cardiometabolism and Venous Diseases
A strong commitment for about four decades
We are dedicated to helping patients address chronic illnesses such as angina, heart failure, diabetes and venous diseases. Having established a trusted presence in these areas, we continue to invest in innovations that enhance patient care.
Leveraging innovative therapies developed through Servier’s global R&D facilities, we strive to make these advanced treatments accessible to meet India’s diverse healthcare needs.
We focus on delivering comprehensive solutions by providing access to high-quality, innovative medicines that support better patient outcomes.
It is a commitment we continue to uphold since the foundation of Servier in India.
Our key brands in Cardiometabolism and Venous Diseases
Oncology
Focused innovative player developing novel & targeted therapies for difficult to treat cancers
We are committed to improving the lives of cancer patients across the country. With India’s rising cancer burden1 , we focus on delivering innovative therapies that address unmet needs, especially for rare and difficult-to-treat cancers. We strive to enhance survival and quality of life by providing treatments that are both effective and well-tolerated. We continue to invest in expanding access to advanced care, ensuring patients receive the best possible support throughout their journey.
In India, we deliver innovative therapies in Pancreatic cancer, IDH1 mutated acute Myeloid Leukaemia (AML) and Cholangiocarcinoma.
Globally, we invest close to 70% of our R&D budget in oncology.
1 Roadmap for making cancer care affordable and accessible in India; EY-FICCI Compendium Recommendations; November 2024; Accessed on 15th July 2025 from efaidnbmnnnibpcajpcglclefindmkaj/ https://www.ey.com/content/dam/ey-unified-site/ey-com/en-in/industries/health/documents/2024/11/ey-ficci-compendium-of-recommendations.pdf
Our key brands in Oncology
